Clinical Trials | June 03, 2026
Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The safety profile was described as manageable, though not without notable toxicities
Fertility platform launches flagship clinic with advanced IVF tech
The approval is supported by results from the Phase 3 SWOG 1826 trial
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
The conference highlighted research suggesting that deuterium levels may influence key biological processes
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
Subscribe To Our Newsletter & Stay Updated
